Bluejay Diagnostics details SYMON-II dataset for IL-6 sepsis mortality risk evaluation

PUBT · 2d ago
Bluejay Diagnostics details SYMON-II dataset for IL-6 sepsis mortality risk evaluation
  • Bluejay Diagnostics released baseline data from its SYMON-II clinical validation study evaluating IL-6 for 28-day mortality risk in sepsis.
  • Results were presented now as dataset details; IL-6 performance results will be reported later following ongoing sample analysis.
  • Preliminary analysis covered 777 patients, showing a clinically meaningful number of deaths to support a mortality-risk evaluation.
  • Non-survivors showed greater illness severity at baseline, supporting the study’s aim to test whether rapid IL-6 results can aid risk assessment.
  • The Symphony IL-6 test remains in development and is not cleared for commercial clinical use in the US.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bluejay Diagnostics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610060630ACCESSWRNAPR_____1232971) on October 06, 2026, and is solely responsible for the information contained therein.